4//SEC Filing
Haines John R 4
Accession 0001209191-21-047515
CIK 0001752828other
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 9:20 PM ET
Size
18.1 KB
Accession
0001209191-21-047515
Insider Transaction Report
Form 4
Celularity IncCELU
Haines John R
Senior Exec Vice President
Transactions
- Award
Stock Option (Right to Buy)
2021-07-16+102,607→ 102,607 totalExercise: $0.28Exp: 2031-07-16→ Class A Common Stock (102,607 underlying) - Award
Stock Option (Right to Buy)
2021-07-16+204,830→ 204,830 totalExercise: $2.87Exp: 2031-07-16→ Class A Common Stock (204,830 underlying) - Award
Stock Option (Right to Buy)
2021-07-16+122,276→ 122,276 totalExercise: $2.87Exp: 2031-07-16→ Class A Common Stock (122,276 underlying) - Award
Stock Option (Right to Buy)
2021-07-16+61,138→ 61,138 totalExercise: $3.88Exp: 2031-07-16→ Class A Common Stock (61,138 underlying) - Award
Stock Option (Right to Buy)
2021-07-16+384,297→ 384,297 totalExercise: $10.21Exp: 2031-07-16→ Class A Common Stock (384,297 underlying)
Footnotes (4)
- [F1]This option is fully vested and exercisable.
- [F2]Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."
- [F3]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 28, 2018, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
- [F4]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, December 15, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
Documents
Issuer
Celularity Inc
CIK 0001752828
Entity typeother
Related Parties
1- filerCIK 0001867686
Filing Metadata
- Form type
- 4
- Filed
- Jul 19, 8:00 PM ET
- Accepted
- Jul 20, 9:20 PM ET
- Size
- 18.1 KB